ArticleClinical chemistry2005
Protein chip array profiling analysis in patients with severe acute respiratory syndrome identified serum amyloid a protein as a biomarker potentially useful in monitoring the extent of pneumonia.
Article in Clinical chemistry, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
51 citing papers in PubMed, 1 synthesis or guideline pooled it.
- The role of biomarkers in diagnosis of COVID-19 - A systematic review.Life sciences · 2020Pooled it
- The Ability of Serum Amyloid A to Discriminate Coronavirus Disease 2019 (COVID-19) Patients Who Stay Moderately Ill Versus Patients Who Become Severely Ill.Journal of clinical laboratory analysis · 2026Article
- Combined serum amyloid A and heparin-binding protein levels on admission reliably predict the severity and outcomes of COVID-19 infection in elderly patients: a retrospective study from Hangzhou, China.Annals of medicine · 2025Article
- IL-6 and SAA-Strong Predictors for the Outcome in COVID-19 CKD Patients.International journal of molecular sciences · 2023Article
- Biomarkers: Promising and valuable tools towards diagnosis, prognosis and treatment of Covid-19 and other diseases.Heliyon · 2023Review
- Oxidative Stress and Inflammatory Status in COVID-19 Outpatients: A Health Center-Based Analytical Cross-Sectional Study.Antioxidants (Basel, Switzerland) · 2022Article
- Review
- Serum amyloid A, ferritin and carcinoembryonic antigen as biomarkers of severity in patients with COVID-19.Biomedical reports · 2022Article
- COVID19 biomarkers: What did we learn from systematic reviews?Frontiers in cellular and infection microbiology · 2022Review
- Role of Serum Amyloid A as a Biomarker for Predicting the Severity and Prognosis of COVID-19.Journal of immunology research · 2022Article
- Biomarkers of ageing and frailty may predict COVID-19 severity.Ageing research reviews · 2022Review
- Role of Polypeptide Inflammatory Biomarkers in the Diagnosis and Monitoring of COVID-19.International journal of peptide research and therapeutics · 2022Review
- Prognostic Factors for COVID-19 Hospitalized Patients with Preexisting Type 2 Diabetes.International journal of endocrinology · 2022Article
- Biomarkers for Prognosis and Treatment Response in COVID-19 Patients.Annals of laboratory medicine · 2021Review
- The most important biomarker associated with coagulation and inflammation among COVID-19 patients.Molecular and cellular biochemistry · 2021Review
- Serum Amyloid A Protein as a useful biomarker to predict COVID-19 patients severity and prognosis.International immunopharmacology · 2021Article
- Infection-Mediated Clinical Biomarkers for a COVID-19 Electrical Biosensing Platform.Sensors (Basel, Switzerland) · 2021Review
- Interferon-γ-induced protein 10 (IP-10) and serum amyloid A (SAA) are excellent biomarkers for the prediction of COVID-19 progression and severity.Life sciences · 2021Article
- Electrochemical sensing: A prognostic tool in the fight against COVID-19.Trends in analytical chemistry : TRAC · 2021Review
- Novel biomarkers for the prediction of COVID-19 progression a retrospective, multi-center cohort study.Virulence · 2020Article
Corrections and comments
- Commented on by
Authors and funding
19 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundA new strain of coronavirus (CoV) has caused an outbreak of severe acute respiratory syndrome (SARS), with 8098 individuals being infected and 774 deaths worldwide. We carried out protein chip array profiling analysis in an attempt to identify biomarkers that might be useful in monitoring the clinical course of SARS patients.
methodsWe performed surface-enhanced laser desorption ionization time-of-flight mass spectrometry on 89 sera collected from 28 SARS patients, 72 sera from 51 control patients with various viral or bacterial infections, and 10 sera from apparently healthy individuals.
resultsNine significantly increased and three significantly decreased serum biomarkers were discovered in the SARS patients compared with the controls. Among these biomarkers, one (11,695 Da) was identified to be serum amyloid A (SAA) protein by peptide mapping and tandem mass spectrometric analysis. When we monitored the SAA concentrations longitudinally in 45 sera from four SARS patients, we found a good correlation of SAA concentration with the extent of pneumonia as assessed by a serial chest x-ray opacity score. Increased SAA occurred in three of four patients at the time of extensive pneumonia as indicated by high x-ray scores. Over the course of gradual recovery in two patients, as assessed clinically and radiologically, SAA concentrations gradually decreased. In the third patient, the concentrations were initially increased, but were further increased with superimposed multiple bacterial infections. SAA was not markedly increased in the fourth patient, who had low x-ray scores and whose clinical course was relatively mild.
conclusionsProtein chip array profiling analysis could be potentially useful in monitoring the severity of disease in SARS patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.